Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
Clinical trial NCT03110328 · COMPLETED
Trial details
- NCT number
- NCT03110328
- Sponsor
- Samsung Medical Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-07
- Primary completion
- 2021-12-30
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.